Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ

HARBIN, China, Aug. 23, 2013 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that S&P Capital IQ has commenced coverage on Yew Bio-Pharm Group. A copy of the nine-page report, which includes an operational review, business summary, financial information, management biographies, and a sub-industry outlook, can be downloaded here: http://www.yewchina.com/En/Article.asp?ColumnId=5&NewsTypeId=11.

"We are pleased to receive professional coverage from such a well-respected company as Standard & Poor's," commented Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio. "We hope that this coverage will be helpful to our current and future investors in understanding and tracking the progress of Yew Bio."

ABOUT S&P CAPITAL IQ

S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.

ABOUT YEW BIO-PHARM GROUP, INC

Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them.

Company Contacts:

Yew Bio-Pharm Group, Inc.

Ms. Sha Jin

Tel: (702) 487-4683

E-mail: hdsusasj@gmail.com

Investor Relations Contacts:

CCG Investor Relations

Mr. John Harmon, CFA, Sr. Account Manager

Tel: +86 (10) 8573 1014 (Beijing)

E-mail: john.harmon@ccgir.com

SOURCE Yew Bio-Pharm Group, Inc.



RELATED LINKS
http://www.yewchina.com/En/Article.asp?ColumnId=5&NewsTypeId=11
http://www.spcapitaliq.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.